Daiichi Sankyo Co Ltd ASCO 2021 Highlights Conference Call Transcript
Thank you for waiting. We are now ready to start Daiichi Sankyo's conference call to present ASCO 2021 highlights. Please note that today's call will be recorded. Dr. Manabe, please go ahead.
Hello colleagues. My name is Sunao Manabe, and I'm the President and CEO of Daiichi Sankyo. Thank you for joining the conference call, focusing on key highlights of the data presented at ASCO 2021.
Today, I present our progress since ASCO 2020 and our new 5-Year Business Plan. Following my presentation, Ken Takeshita, our Global R&D Head, will present about R&D. And today's event will be his debut in his new role so please look forward to it.
Please see Slide 3. This slide shows the progress of our 3 ADCs since ASCO 2020. With respect to Enhertu through the strategic alliance with AstraZeneca, addition of launched countries and new indications as well as clinical development are all proceeding smoothly. As for breast cancer indication, we have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |